Tempol (4-hydroxy tempo) protects mice from cisplatin-induced acute kidney injury via modulation of expression of aquaporins and kidney injury molecule-1

References

• Abdel-Wahab, W.M., and Moussa, F.I., 2019. Neuroprotective effect of N-acetylcysteine against cisplatin-induced toxicity in rat brain by modulation of oxidative stress and inflammation. Drug Design, Development and Therapy, 13, 1155–1162.
   PubMed Web of Science ®Google Scholar
• Abdi, S.H.A., et al., 2018. S-allyl cysteine ameliorates cyclophosphamide-induced downregulation of urothelial uroplakin IIIa with a concomitant effect on expression and release of CCL11and TNF-α in mice. Pharmacological Reports, 70 (4), 769–776.
   PubMed Web of Science ®Google Scholar
• Afjal, M.A., et al., 2019. Anti-inflammatory role of tempol (4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl) in nephroprotection. Human & Experimental Toxicology, 38 (6), 713–723.
   PubMed Web of Science ®Google Scholar
• Ahmed, L.A., et al., 2014. Tempol, a superoxide dismutase mimetic agent, ameliorates cisplatin-induced nephrotoxicity through alleviation of mitochondrial dysfunction in mice. PLoS One, 9 (10), e108889.
   PubMed Web of Science ®Google Scholar
• Alzoubi, K.H., et al., 2014. Tempol prevents genotoxicity induced by vorinostat: role of oxidative DNA damage. Cytotechnology, 66 (3), 449–455.
   PubMed Web of Science ®Google Scholar
• Arunkumar, P.A., et al., 2012. Science behind cisplatin-induced nephrotoxicity in humans: a clinical study. Asian Pacific Journal of Tropical Biomedicine, 2 (8), 640–644.
   PubMedGoogle Scholar
• Barabas, K., et al., 2008. Cisplatin: a review of toxicities and therapeutic applications. Veterinary and Comparative Oncology, 6 (1), 1–18.
   PubMed Web of Science ®Google Scholar
• Bernardy, C., et al., 2017. Tempol, a superoxide dismutase mimetic agent, inhibits superoxide anion-induced inflammatory pain in mice. BioMed Research International, 2017, 9584819.
   PubMed Web of Science ®Google Scholar
• Bonventre, J.V., 2009. Kidney injury molecule-1 (KIM-1): a urinary biomarker and much more. Nephrology Dialysis Transplantation, 24 (11), 3265–3268.
   PubMed Web of Science ®Google Scholar
• Bustin, S.A., et al., 2009. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clinical Chemistry, 55 (4), 611–622.
   PubMed Web of Science ®Google Scholar
• Chen, B., et al., 2015. Epigallocatechin-3-gallate protects against cisplatin-induced nephrotoxicity by inhibiting endoplasmic reticulum stress-induced apoptosis. Experimental Biology and Medicine, 240 (11), 1513–1519.
   Web of Science ®Google Scholar
• Dasari, S., and Tchounwou, P.B., 2014. Cisplatin in cancer therapy: molecular mechanisms of action. European Journal of Pharmacology, 740, 364–378.
   PubMed Web of Science ®Google Scholar
• De Blasio, M. J., et al., 2017. The superoxide dismutase mimetic tempol blunts diabetes-induced upregulation of NADPH oxidase and endoplasmic reticulum stress in a rat model of diabetic nephropathy. European Journal of Pharmacology, 807, 12–20.
   PubMed Web of Science ®Google Scholar
• Duffy, E.A., et al., 2018. Nephrotoxicity: evidence in patients receiving cisplatin therapy. Clinical Journal of Oncology Nursing, 22 (2), 175–183.
   PubMed Web of Science ®Google Scholar
• Galgamuwa, R., et al., 2016. Dichloroacetate prevents cisplatin-induced nephrotoxicity without compromising cisplatin anticancer properties. Journal of the American Society of Nephrology , 27 (11), 3331–3344.
   PubMed Web of Science ®Google Scholar
• Gao, J., et al., 2017. L-Carnitine ameliorates the decrease of aquaporin 2 levels in rats with cisplatin-induced kidney injury. Nephron, 135 (4), 315–325.
   PubMed Web of Science ®Google Scholar
• George, B., Joy, M.S., and Aleksunes, L.M., 2018. Urinary protein biomarkers of kidney injury in patients receiving cisplatin chemotherapy. Experimental Biology and Medicine, 243 (3), 272–282.
   Web of Science ®Google Scholar
• Grassi, D., et al., 2013. Estradiol and testosterone regulate arginine-vasopressin expression in SH-SY5Y human female neuroblastoma cells through estrogen receptors-α and -β. Endocrinology, 154 (6), 2092–2100.
   PubMed Web of Science ®Google Scholar
• He, J., and Yang, B., 2019. Aquaporins in renal diseases. International Journal of Molecular Sciences, 20 (2), 366.
   PubMed Web of Science ®Google Scholar
• Humanes, B., et al., 2017. Cisplatin-induced renal inflammation is ameliorated by cilastatin nephroprotection. Nephrology, Dialysis, Transplantation, 32 (10), 1645–1655.
   PubMed Web of Science ®Google Scholar
• Ikeda, M., and Matsuzaki, T., 2015. Regulation of aquaporins by vasopressin in the kidney. Vitamins and Hormones, 98, 307–337.
   PubMed Web of Science ®Google Scholar
• Inoue, T., Nonoguchi, H., and Tomita, K., 2001. Physiological effects of vasopressin and atrial natriuretic peptide in the collecting duct. Cardiovascular Research, 51 (3), 470–480.
   PubMed Web of Science ®Google Scholar
• Kandemir, F.M., et al., 2019. Protective effects of zingerone on cisplatin-induced nephrotoxicity in female rats. Environmental Science and Pollution Research International, 26 (22), 22562–22574.
   PubMed Web of Science ®Google Scholar
• Kang, D.G., et al., 2004. Butein ameliorates renal concentrating ability in cisplatin-induced acute renal failure in rats. Biological & Pharmaceutical Bulletin, 27 (3), 366–370.
   PubMed Web of Science ®Google Scholar
• Karanovic, D., et al., 2016. Effects of single and combined losartan and tempol treatments on oxidative stress, kidney structure and function in spontaneously hypertensive rats with early course of proteinuric nephropathy. PLoS One, 11 (8), e0161706.
   PubMed Web of Science ®Google Scholar
• Khattab, M.M., 2006. TEMPOL, a membrane-permeable radical scavenger, attenuates peroxynitrite- and superoxide anion-enhanced carrageenan-induced paw edema and hyperalgesia: a key role for superoxide anion. European Journal of Pharmacology, 548 (1–3), 167–173.
   Google Scholar
• Kim, S.W., et al., 2001. Cisplatin decreases the abundance of aquaporin water channels in rat kidney. Journal of the American Society of Nephrology, 12 (5), 875–882.
   PubMed Web of Science ®Google Scholar
• Kishore, B.K., et al., 2000. Expression of renal aquaporins 1, 2, and 3 in a rat model of cisplatin-induced polyuria. Kidney International, 58 (2), 701–711.
   PubMed Web of Science ®Google Scholar
• Lameire, N.H., et al., 2013. Acute kidney injury: an increasing global concern. Lancet, 382 (9887), 170–179.
   PubMed Web of Science ®Google Scholar
• Livak, K.J., and Schmittgen, T.D., 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25 (4), 402–408.
   PubMed Web of Science ®Google Scholar
• Miller, R.P., et al., 2010. Mechanisms of cisplatin nephrotoxicity. Toxins, 2 (11), 2490–2518.
   PubMed Web of Science ®Google Scholar
• Nielsen, S., et al., 1995. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proceedings of the National Academy of Sciences of the United States of America, 92 (4), 1013–1017.
   PubMed Web of Science ®Google Scholar
• Onuma, S., and Nakanishi, K., 2004. Superoxide dismustase mimetic tempol decreases blood pressure by increasing renal medullary blood flow in hyperinsulinemic-hypertensive rats. Metabolism: Clinical and Experimental, 53 (10), 1305–1308.
   PubMed Web of Science ®Google Scholar
• Oronsky, B., et al., 2017. Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management. Cancer Chemotherapy and Pharmacology, 80 (5), 895–907.
   PubMed Web of Science ®Google Scholar
• Perše, M., and Večerić-Haler, Ž., 2018. Cisplatin-induced rodent model of kidney injury: characteristics and challenges. BioMed Research International, 2018, 1462802.
   PubMed Web of Science ®Google Scholar
• Sohn, S.J., et al., 2013. In vitro evaluation of biomarkers for cisplatin-induced nephrotoxicity using HK-2 human kidney epithelial cells. Toxicology Letters, 217 (3), 235–242.
   PubMed Web of Science ®Google Scholar
• Soni, H., et al., 2018. Cisplatin-induced oxidative stress stimulates renal Fas ligand shedding. Renal Failure, 40 (1), 314–322.
   PubMed Web of Science ®Google Scholar
• Sonoda, H., Oshikawa-Hori, S., and Ikeda, M., 2019. An early decrease in release of aquaporin-2 in urinary extracellular vesicles after cisplatin treatment in rats. Cells, 8 (2), 139.
   PubMed Web of Science ®Google Scholar
• van Angelen, A.A., et al., 2013. Cisplatin-induced injury of the renal distal convoluted tubule is associated with hypomagnesaemia in mice. Nephrology Dialysis Transplantation, 28 (4), 879–889.
   PubMed Web of Science ®Google Scholar
• Volarevic, V., et al., 2019. Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity. Journal of Biomedical Science, 26 (1), 25.
   PubMed Web of Science ®Google Scholar
• Yan, W., et al., 2017. Renoprotective mechanisms of Astragaloside IV in cisplatin-induced acute kidney injury. Free Radical Research, 51 (7–8), 669–683.
   PubMed Web of Science ®Google Scholar
• Yao, X., et al., 2007. Cisplatin nephrotoxicity: a review. The American Journal of the Medical Sciences, 334 (2), 115–124.
   PubMed Web of Science ®Google Scholar
• Youn, C.K., et al., 2016. Protective effect of tempol against cisplatin-induced ototoxicity. International Journal of Molecular Sciences, 17 (11), 1931.
   PubMed Web of Science ®Google Scholar
• Zhang, P.L., et al., 2008. Kidney injury molecule-1 expression in transplant biopsies is a sensitive measure of cell injury. Kidney International, 73 (5), 608–614.
   PubMed Web of Science ®Google Scholar